X0202 SCHEDULE 13G/A 0000902664-25-005039 0001784547 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 06/30/2026 0001833214 SAB Biotherapeutics, Inc. 78397T202 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 Rule 13d-1(b) Woodline Partners LP DE 5455355.00 0.00 5455355.00 0.00 5455355.00 N 6.8 IA PN Consists of (i) 1,180,355 shares of Common Stock (as defined in Item 2(a)), (ii) 2,850,000 shares of Common Stock issuable upon conversion of 28,500 shares of Series B preferred stock (the "Series B Preferred Stock") underlying 28,500 enrollment warrants (the "Enrollment Warrants") and (iii) 1,425,000 shares of Common Stock issuable upon conversion of 14,250 shares of Series B Preferred Stock underlying 14,250 data release warrants (the "Data Release Warrants"). SAB Biotherapeutics, Inc. 777 W 41st St, Suite 401, Miami Beach, Florida 33140 This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of SAB Biotherapeutics, Inc. (the "Company"), and shares of Common Stock issuable upon the conversion of Series B Preferred Stock issuable upon the exercise of the Data Release Warrants and Enrollment Warrants, directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein. The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. Woodline Partners is a Delaware limited partnership. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 76,464,094 shares of Common Stock outstanding as of May 6, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026, and assumes the conversion of the Series B Preferred Stock issuable upon the exercise of the Enrollment Warrants and the Data Release Warrants held by the Woodline Fund. 6.8% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). The Woodline Fund has right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Woodline Partners LP /s/ Erin Mullen 08/14/2026